Corvus Pharmaceuticals, Inc. (CRVS)
13.93
-0.46
(-3.20%)
USD |
NASDAQ |
Sep 08, 16:00
14.00
+0.07
(+0.50%)
Pre-Market: 09:15
Corvus Pharmaceuticals Enterprise Value : 957.30M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 957.30M |
| September 04, 2026 | 996.00M |
| September 03, 2026 | 1.018B |
| September 02, 2026 | 980.02M |
| September 01, 2026 | 985.91M |
| August 31, 2026 | 966.56M |
| August 28, 2026 | 976.65M |
| August 27, 2026 | 1.024B |
| August 26, 2026 | 1.025B |
| August 25, 2026 | 1.010B |
| August 24, 2026 | 970.76M |
| August 21, 2026 | 1.002B |
| August 20, 2026 | 990.95M |
| August 19, 2026 | 1.081B |
| August 18, 2026 | 1.033B |
| August 17, 2026 | 1.040B |
| August 14, 2026 | 1.038B |
| August 13, 2026 | 1.059B |
| August 12, 2026 | 1.052B |
| August 11, 2026 | 1.025B |
| August 10, 2026 | 941.32M |
| August 07, 2026 | 956.46M |
| August 06, 2026 | 951.42M |
| August 05, 2026 | 957.30M |
| August 04, 2026 | 956.46M |
| Date | Value |
|---|---|
| August 03, 2026 | 910.20M |
| July 31, 2026 | 900.94M |
| July 30, 2026 | 895.05M |
| July 29, 2026 | 882.44M |
| July 28, 2026 | 905.15M |
| July 27, 2026 | 872.34M |
| July 24, 2026 | 884.96M |
| July 23, 2026 | 936.27M |
| July 22, 2026 | 962.35M |
| July 21, 2026 | 1.003B |
| July 20, 2026 | 971.60M |
| July 17, 2026 | 1.039B |
| July 16, 2026 | 985.91M |
| July 15, 2026 | 1.041B |
| July 14, 2026 | 1.045B |
| July 13, 2026 | 1.023B |
| July 10, 2026 | 1.104B |
| July 09, 2026 | 1.148B |
| July 08, 2026 | 1.138B |
| July 07, 2026 | 1.100B |
| July 06, 2026 | 1.062B |
| July 02, 2026 | 1.067B |
| July 01, 2026 | 1.027B |
| June 30, 2026 | 1.042B |
| June 29, 2026 | 981.75M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.96M |
| Total Expenses (Quarterly) | 17.96M |
| EPS Diluted (Quarterly) | -0.1944 |
| Earnings Yield | -4.43% |
| Normalized Earnings Yield | -4.434 |